- Home
- TOVX vs KLTOW Comparison
TOVX vs KLTOW Comparison
Compare TOVX & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOVX | KLTOW |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | N/A |
| IPO Year | 2006 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TOVX | KLTOW |
|---|---|---|
| Price | $0.22 | $0.13 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | N/A |
| Earning Date | 11-12-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | N/A |
| 52 Week High | $2.08 | N/A |
Technical Indicators
Market Signals| Indicator | TOVX | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 44.16 |
| Support Level | $0.21 | $0.13 |
| Resistance Level | $0.24 | $0.15 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 25.70 | 11.61 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.